In the lab, it’s easier to grow simple balls of cells than complex asymmetrical structures with two distinct ends—like the one million filtering units—nephrons—that make up a human kidney. But new research unveils a blueprint that makes it possible to generate specific kidney cell types on demand—cells that hold immense value for preclinical studies of new therapeutics, congenital kidney diseases, and drug-induced nephrotoxicity.
Stem cell scientists unlock blueprint for lab-grown kidney cells with preclinical value
